Hematopoietic stem cell transplant (HSCT) is often performed as a treatment modality for cancers involving blood or bone marrow, including multiple myelomas and various forms of leukemias. One of the complications following HSCT is thrombotic microangiopathy (TMA), in which there is endothelial injury due to multiple factors, leading to microangiopathic hemolytic anemia, intravascular platelet activation, and formation of thrombi within the microcirculation. HSCT-TMA is associated with end-organ injury involving kidney, lungs, and gastro-intestinal tract among others, primarily due to ischemia and activation of complement cascade.
Our client was interested to understand the mortality, survival, and other long-term outcomes among patients with HSCT-TMA. For this project, we performed literature screening of nearly 1400 articles over 2 rounds and identified the records that contained the most relevant information pertaining to the objectives of the review.
Therapy area: Oncology, Hematology